News articles about OncoGenex Pharmaceuticals (NASDAQ:OGXI) have been trending very positive this week, according to Alpha One Sentiment Analysis. Alpha One, a service of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a news sentiment score of 0.56 on Alpha One’s scale. Alpha One also assigned media coverage about the biopharmaceutical company an impact score of 75 out of 100, indicating that recent media coverage is likely to have an impact on the company’s share price in the near term.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) traded up 0.3143% during midday trading on Friday, reaching $0.3511. 31,215 shares of the company were exchanged. The stock’s market capitalization is $10.56 million. The firm’s 50 day moving average price is $0.39 and its 200-day moving average price is $0.48. OncoGenex Pharmaceuticals has a 52 week low of $0.33 and a 52 week high of $1.32.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) last released its quarterly earnings data on Monday, May 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.18. OncoGenex Pharmaceuticals had a negative return on equity of 50.34% and a negative net margin of 94.64%. Equities analysts forecast that OncoGenex Pharmaceuticals will post ($0.78) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Very Favorable Press Coverage Likely to Affect OncoGenex Pharmaceuticals (OGXI) Stock Price” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at

OncoGenex Pharmaceuticals Company Profile

OncoGenex Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

5 Day Chart for NASDAQ:OGXI

Receive News & Stock Ratings for OncoGenex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.